BridgeBio Pharma (NASDAQ:BBIO) just reported results for the first quarter of 2024.
- BridgeBio Pharma reported earnings per share of -20 cents. This was above the analyst estimate for EPS of -89 cents.
- The company reported revenue of $211.12 million.
- This was 1,404.78% better than the analyst estimate for revenue of $14.03 million.